|
US5783682A
(en)
*
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
|
US5877278A
(en)
*
|
1992-09-24 |
1999-03-02 |
Chiron Corporation |
Synthesis of N-substituted oligomers
|
|
US6133444A
(en)
|
1993-12-22 |
2000-10-17 |
Perseptive Biosystems, Inc. |
Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
|
|
US7034110B2
(en)
|
1994-01-05 |
2006-04-25 |
Arqule, Inc. |
Method of identifying chemical compounds having selected properties for a particular application
|
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
|
DE4408533A1
(de)
*
|
1994-03-14 |
1995-09-28 |
Hoechst Ag |
PNA-Synthese unter Verwendung einer basenlabilen Amino-Schutzgruppe
|
|
US5695934A
(en)
*
|
1994-10-13 |
1997-12-09 |
Lynx Therapeutics, Inc. |
Massively parallel sequencing of sorted polynucleotides
|
|
US5712171A
(en)
|
1995-01-20 |
1998-01-27 |
Arqule, Inc. |
Method of generating a plurality of chemical compounds in a spatially arranged array
|
|
WO1996040709A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Perseptive Biosystems, Inc. |
Pna-dna chimeras and pna synthons for their preparation
|
|
US6506906B1
(en)
|
1996-02-26 |
2003-01-14 |
California Institute Of Technology |
Preparation and use of bifunctional molecules having DNA sequence binding specificity
|
|
US6555692B1
(en)
|
1996-02-26 |
2003-04-29 |
California Institute Of Technology |
Preparation and use of bifunctional molecules having DNA sequence binding specificity
|
|
WO1998045284A1
(en)
|
1996-02-26 |
1998-10-15 |
California Institute Of Technology |
Stereochemical control of the dna binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove
|
|
US6143901A
(en)
*
|
1996-07-31 |
2000-11-07 |
Genesoft, Inc. |
Complex formation between dsDNA and pyrrole imidazole polyamides
|
|
JP2001513759A
(ja)
|
1996-02-26 |
2001-09-04 |
カリフォルニア・インスティチュート・オブ・テクノロジー |
二本鎖ｄｎａの副溝において結合する改良されたポリアミド
|
|
US6090947A
(en)
|
1996-02-26 |
2000-07-18 |
California Institute Of Technology |
Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
|
|
US5763424A
(en)
*
|
1996-03-26 |
1998-06-09 |
Gilead Sciences, Inc. |
Composition and method for storing nucleotide analogs
|
|
US20040171028A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
WO2005121370A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that facilitate risc loading
|
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US6528098B2
(en)
|
1996-10-22 |
2003-03-04 |
Advanced Viral Research Corp. |
Preparation of a therapeutic composition
|
|
US6617114B1
(en)
|
1996-10-31 |
2003-09-09 |
Karo Bio Ab |
Identification of drug complementary combinatorial libraries
|
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
|
US6617422B1
(en)
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
|
EP1387390B1
(de)
|
1997-06-20 |
2009-02-18 |
Bio - Rad Laboratories, Inc. |
Retentatchromatographievorrichtung und Proteinchipmatrizen mit Anwendungen in Biologie und Medizin
|
|
NZ516848A
(en)
|
1997-06-20 |
2004-03-26 |
Ciphergen Biosystems Inc |
Retentate chromatography apparatus with applications in biology and medicine
|
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
|
US5877309A
(en)
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
US6960457B1
(en)
*
|
1997-09-04 |
2005-11-01 |
Stanford University |
Reversible immobilization of arginine-tagged moieties on a silicate surface
|
|
US7252950B1
(en)
|
1997-09-04 |
2007-08-07 |
The Regents Of The University Of California |
Assays for detecting modulators of cytoskeletal function
|
|
US6300318B1
(en)
|
1997-09-16 |
2001-10-09 |
Peter E. Nielsen |
Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
|
|
US6485901B1
(en)
|
1997-10-27 |
2002-11-26 |
Boston Probes, Inc. |
Methods, kits and compositions pertaining to linear beacons
|
|
EP1025120B1
(de)
*
|
1997-10-27 |
2010-08-18 |
Boston Probes, Inc. |
Sich auf "pna molecular beacons" beziehende verfahren, testsätze und zusammensetzungen
|
|
US6190920B1
(en)
|
1997-11-12 |
2001-02-20 |
The Regents Of The University Of California |
Method for detecting enzyme catalyzed cyclization
|
|
US6177558B1
(en)
*
|
1997-11-13 |
2001-01-23 |
Protogene Laboratories, Inc. |
Method and composition for chemical synthesis using high boiling point organic solvents to control evaporation
|
|
WO1999047923A2
(en)
*
|
1998-03-20 |
1999-09-23 |
The Rockefeller University |
Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
|
|
WO1999049293A2
(en)
|
1998-03-24 |
1999-09-30 |
Boston Probes, Inc. |
Methods, kits and compositions pertaining to detection complexes
|
|
US20040063618A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Muthiah Manoharan |
Peptide nucleic acids having improved uptake and tissue distribution
|
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US6699969B1
(en)
|
1998-04-14 |
2004-03-02 |
The Regents Of The University Of California |
Assays for the detection of microtubule depolymerization inhibitors
|
|
US6872537B1
(en)
|
1998-04-14 |
2005-03-29 |
Regents Of The University Of California |
Assays for the detection of microtubule depolymerization inhibitors
|
|
US6410687B1
(en)
|
1998-04-14 |
2002-06-25 |
The Regents Of The University Of California |
Polypeptides for the detection of microtubule depolymerization inhibitors
|
|
US7094943B2
(en)
|
1998-04-27 |
2006-08-22 |
Hubert Köster |
Solution phase biopolymer synthesis
|
|
DE19819735A1
(de)
*
|
1998-05-02 |
1999-11-04 |
Novartis Ag |
Vorrichtung und Verfahren zur Herstellung einer Anordnung von Kettenmolekülen auf einem Trägermaterial
|
|
US6324479B1
(en)
|
1998-05-08 |
2001-11-27 |
Rosetta Impharmatics, Inc. |
Methods of determining protein activity levels using gene expression profiles
|
|
WO1999060012A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
|
AU4965499A
(en)
*
|
1998-07-09 |
2000-02-01 |
Biocept, Inc. |
Method of using an improved peptide nucleic acid universal library to optimize dna sequence hybridation
|
|
US6171794B1
(en)
|
1998-07-13 |
2001-01-09 |
Rosetta Inpharmatics, Inc. |
Methods for determining cross-hybridization
|
|
US7402400B2
(en)
|
2001-07-03 |
2008-07-22 |
Regents Of The University Of California |
Mammalian sweet taste receptors
|
|
US6146830A
(en)
|
1998-09-23 |
2000-11-14 |
Rosetta Inpharmatics, Inc. |
Method for determining the presence of a number of primary targets of a drug
|
|
US6950752B1
(en)
|
1998-10-27 |
2005-09-27 |
Rosetta Inpharmatics Llc |
Methods for removing artifact from biological profiles
|
|
US6468476B1
(en)
*
|
1998-10-27 |
2002-10-22 |
Rosetta Inpharmatics, Inc. |
Methods for using-co-regulated genesets to enhance detection and classification of gene expression patterns
|
|
US6203987B1
(en)
|
1998-10-27 |
2001-03-20 |
Rosetta Inpharmatics, Inc. |
Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
|
|
US6492111B1
(en)
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
|
US6801859B1
(en)
|
1998-12-23 |
2004-10-05 |
Rosetta Inpharmatics Llc |
Methods of characterizing drug activities using consensus profiles
|
|
US6222093B1
(en)
*
|
1998-12-28 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Methods for determining therapeutic index from gene expression profiles
|
|
US6370478B1
(en)
|
1998-12-28 |
2002-04-09 |
Rosetta Inpharmatics, Inc. |
Methods for drug interaction prediction using biological response profiles
|
|
US6359061B1
(en)
|
1999-03-19 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Amide compound libraries
|
|
AU5291600A
(en)
|
1999-06-01 |
2000-12-18 |
Caliper Technologies Corporation |
Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
|
|
US7371516B1
(en)
|
1999-07-16 |
2008-05-13 |
Rosetta Inpharmatics Llc |
Methods for determining the specificity and sensitivity of oligonucleo tides for hybridization
|
|
US7013221B1
(en)
|
1999-07-16 |
2006-03-14 |
Rosetta Inpharmatics Llc |
Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
|
|
US6312956B1
(en)
|
1999-10-01 |
2001-11-06 |
Vanderbilt University |
Nuclear targeted peptide nucleic acid oligomer
|
|
EP1950306A1
(de)
|
1999-11-17 |
2008-07-30 |
Mendel Biotechnology, Inc. |
Umweltstress-Toleranzgene
|
|
AU780463B2
(en)
|
1999-11-17 |
2005-03-24 |
Mendel Biotechnology, Inc. |
Environmental stress tolerance genes
|
|
US6458538B1
(en)
|
1999-12-14 |
2002-10-01 |
Ptc Therapeutics, Inc. |
Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
|
|
US8642284B1
(en)
|
1999-12-15 |
2014-02-04 |
Massachusetts Institute Of Technology |
Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
|
|
US7452664B2
(en)
*
|
1999-12-15 |
2008-11-18 |
Massachusetts Institute Of Technology |
Methods for identifying agents which alter histone protein acetylation
|
|
TW201006846A
(en)
|
2000-03-07 |
2010-02-16 |
Senomyx Inc |
T1R taste receptor and genes encidung same
|
|
US7115738B2
(en)
|
2000-03-14 |
2006-10-03 |
Active Motif |
Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use
|
|
US20040014644A1
(en)
*
|
2000-03-14 |
2004-01-22 |
Vladimir Efimov |
Oligonucleotide analogues and methods of use for modulating gene expression
|
|
US6962906B2
(en)
*
|
2000-03-14 |
2005-11-08 |
Active Motif |
Oligonucleotide analogues, methods of synthesis and methods of use
|
|
AU2001271720A1
(en)
*
|
2000-07-05 |
2002-01-14 |
Rosetta Inpharmatics, Inc. |
Methods and compositions for determining gene function
|
|
WO2002015675A1
(en)
|
2000-08-22 |
2002-02-28 |
Mendel Biotechnology, Inc. |
Genes for modifying plant traits iv
|
|
US6713257B2
(en)
|
2000-08-25 |
2004-03-30 |
Rosetta Inpharmatics Llc |
Gene discovery using microarrays
|
|
US7807447B1
(en)
|
2000-08-25 |
2010-10-05 |
Merck Sharp & Dohme Corp. |
Compositions and methods for exon profiling
|
|
AU2001294654A1
(en)
*
|
2000-09-25 |
2002-04-08 |
The Regents Of The University Of California |
Model for neurodegenerative diseases involving amyloid accumulation
|
|
EP1326892A2
(de)
|
2000-10-12 |
2003-07-16 |
University of Rochester |
Zusammensetzungen die die proliferation von krebszellen hemmen
|
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
|
US7572575B2
(en)
*
|
2000-12-13 |
2009-08-11 |
Massachusetts Institute Of Technology |
SIR2 activity
|
|
TW201022287A
(en)
|
2001-01-03 |
2010-06-16 |
Senomyx Inc |
T1R taste receptors and genes encoding same
|
|
EP1748078B1
(de)
*
|
2001-03-09 |
2011-01-19 |
Boston Probes, Inc. |
Kombinationsoligomere betreffende Verfahren, Kits und Zusammensetzungen
|
|
US20030170642A1
(en)
*
|
2001-03-12 |
2003-09-11 |
Irm, Llc |
Identification of cellular targets for biologically active molecules
|
|
WO2002072789A2
(en)
*
|
2001-03-12 |
2002-09-19 |
Irm, Llc. |
Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
|
|
US7883856B2
(en)
|
2001-04-05 |
2011-02-08 |
Senomyx Inc. |
Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
US20020155587A1
(en)
|
2001-04-20 |
2002-10-24 |
Sequenom, Inc. |
System and method for testing a biological sample
|
|
US7803982B2
(en)
|
2001-04-20 |
2010-09-28 |
The Mount Sinai School Of Medicine Of New York University |
T1R3 transgenic animals, cells and related methods
|
|
EP1572871A4
(de)
*
|
2001-04-20 |
2007-11-14 |
Sinai School Medicine |
T1r3, ein neuer geschmacksrezeptor
|
|
SG2011071982A
(en)
|
2001-05-25 |
2016-09-29 |
Univ Duke |
Modulators of pharmacological agents
|
|
US7294478B1
(en)
|
2001-06-06 |
2007-11-13 |
Rosetta Inpharmatics Llc |
Microarray reaction cartridge
|
|
US20030104426A1
(en)
*
|
2001-06-18 |
2003-06-05 |
Linsley Peter S. |
Signature genes in chronic myelogenous leukemia
|
|
US7171311B2
(en)
*
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
|
AU2002316251A1
(en)
*
|
2001-06-18 |
2003-01-02 |
Rosetta Inpharmatics, Inc. |
Diagnosis and prognosis of breast cancer patients
|
|
WO2003001876A2
(en)
|
2001-06-26 |
2003-01-09 |
Senomyx, Inc. |
T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
|
|
US9261460B2
(en)
|
2002-03-12 |
2016-02-16 |
Enzo Life Sciences, Inc. |
Real-time nucleic acid detection processes and compositions
|
|
US9777312B2
(en)
*
|
2001-06-30 |
2017-10-03 |
Enzo Life Sciences, Inc. |
Dual polarity analysis of nucleic acids
|
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
|
US6691042B2
(en)
|
2001-07-02 |
2004-02-10 |
Rosetta Inpharmatics Llc |
Methods for generating differential profiles by combining data obtained in separate measurements
|
|
US7348140B1
(en)
|
2001-07-25 |
2008-03-25 |
Acadia Pharmaceuticals, Inc. |
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
|
|
US7413870B2
(en)
|
2001-08-01 |
2008-08-19 |
Rigel Pharmaceuticals, Incorporated |
SAK: modulation of cellular proliferation for treatment of cancer
|
|
US20030124196A1
(en)
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
|
US20070059688A1
(en)
*
|
2001-10-12 |
2007-03-15 |
Rozengurt Juan E |
Gastrointestinal chemosensory receptors
|
|
US7871619B2
(en)
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
WO2003048341A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Uab Research Foundation |
Cap-gly domain structure and uses thereof
|
|
DK1458888T3
(da)
*
|
2001-12-10 |
2011-06-20 |
Novartis Ag |
Fremgangsmåder til behandling af psykose og skizofreni baseret på polymorfier i CNTF-genet
|
|
JP2005523688A
(ja)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
|
|
KR100464261B1
(ko)
*
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7418351B2
(en)
*
|
2002-01-31 |
2008-08-26 |
Rosetta Inpharmatics Llc |
Methods for analysis of measurement errors in measured signals
|
|
CA2474982A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Rosetta Inpharmatics Llc |
Computer systems and methods for identifying genes and determining pathways associated with traits
|
|
MXPA04007586A
(es)
|
2002-02-06 |
2005-06-08 |
Vicor Technologies Inc |
Moleculas anti-infarto.
|
|
EP1534729A2
(de)
*
|
2002-02-26 |
2005-06-01 |
University of Utah Research Foundation |
Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
|
|
US7091331B2
(en)
|
2002-03-04 |
2006-08-15 |
Bristol-Myers Squibb Company |
Nucleic acid molecules and polypeptides encoding baboon TAFI
|
|
US9353405B2
(en)
|
2002-03-12 |
2016-05-31 |
Enzo Life Sciences, Inc. |
Optimized real time nucleic acid detection processes
|
|
KR20030084444A
(ko)
*
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US20040005613A1
(en)
*
|
2002-05-22 |
2004-01-08 |
Norton Michael L. |
Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
|
|
US7893218B2
(en)
|
2003-06-16 |
2011-02-22 |
Stowers Institute For Medical Research |
Antibodies that specifically bind SOST peptides
|
|
US20050287648A1
(en)
|
2002-08-05 |
2005-12-29 |
University Of Rochester |
Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
|
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
BR0314389A
(pt)
|
2002-09-18 |
2005-07-12 |
Mendel Biotechnology Inc |
Polinucleotìdeos e polipeptìdeos em plantas
|
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
|
RU2005118421A
(ru)
|
2002-11-15 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
2'-разветвленные нуклеозиды и мутация flaviviridae
|
|
AU2003294315A1
(en)
*
|
2002-11-19 |
2004-06-15 |
Amgen Inc. |
Amplified genes involved in cancer
|
|
CN1738914A
(zh)
|
2002-11-21 |
2006-02-22 |
震源技术公司 |
使用编码双链启动子一条链的引物的方法
|
|
US20040259111A1
(en)
*
|
2002-12-10 |
2004-12-23 |
Rosetta Inpharmatics Llc |
Automated system and method for preparing an assay ready biological sample
|
|
AU2004206250B8
(en)
*
|
2003-01-21 |
2009-09-17 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
|
US7996155B2
(en)
|
2003-01-22 |
2011-08-09 |
Microsoft Corporation |
ANOVA method for data analysis
|
|
EP2216407B1
(de)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutische Zusammensetzungen
|
|
EP2664672A1
(de)
|
2003-04-17 |
2013-11-20 |
Alnylam Pharmaceuticals Inc. |
Modifizierte iRNA-Wirkstoffe
|
|
EP1628993A4
(de)
*
|
2003-05-16 |
2010-04-07 |
Rosetta Inpharmatics Llc |
Verfahren und zusammensetzungen zur rna-interfrenz
|
|
WO2005020784A2
(en)
*
|
2003-05-23 |
2005-03-10 |
Mount Sinai School Of Medicine Of New York University |
Surrogate cell gene expression signatures for evaluating the physical state of a subject
|
|
NZ572940A
(en)
|
2003-05-30 |
2010-04-30 |
Agensys Inc |
Prostate stem cell antigen (PSCA) variants and subsequences thereof
|
|
EP1636384A4
(de)
*
|
2003-06-20 |
2007-03-07 |
Amgen Inc |
Genamplifikation und überexpression bei krebs
|
|
WO2005002527A2
(en)
*
|
2003-07-03 |
2005-01-13 |
Massachusetts Institute Of Technology |
Sirt1 modulation of adipogenesis and adipose function
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
AU2004263871B2
(en)
*
|
2003-08-06 |
2011-07-14 |
Senomyx, Inc. |
T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
|
|
US7269517B2
(en)
*
|
2003-09-05 |
2007-09-11 |
Rosetta Inpharmatics Llc |
Computer systems and methods for analyzing experiment design
|
|
EP1671121A4
(de)
|
2003-09-29 |
2007-12-19 |
Pathwork Diagnostics Inc |
Systeme und verfahren zum nachweis biologischer merkmale
|
|
US20050244810A1
(en)
*
|
2003-09-29 |
2005-11-03 |
Egan Josephine M |
Taste signaling in gastrointestinal cells
|
|
EP2369347A1
(de)
|
2003-11-07 |
2011-09-28 |
Ciphergen Biosystems, Inc. |
Biomarker für Morbus Alzheimer
|
|
US20050164969A1
(en)
*
|
2003-11-19 |
2005-07-28 |
Massachusetts Institute Of Technology |
Method of extending life span
|
|
EP3427585B1
(de)
|
2003-11-26 |
2024-10-16 |
University of Massachusetts |
Sequenzspezifische hemmung der kleinen rna-funktion
|
|
EP1711618B1
(de)
|
2003-12-23 |
2010-08-04 |
Mount Sinai Hospital Corporation |
Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
|
|
WO2005060739A1
(en)
|
2003-12-24 |
2005-07-07 |
G2 Inflammation Pty Ltd |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
CN1964740A
(zh)
|
2004-04-02 |
2007-05-16 |
加利福尼亚大学董事会 |
治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
US7939251B2
(en)
|
2004-05-06 |
2011-05-10 |
Roche Molecular Systems, Inc. |
SENP1 as a marker for cancer
|
|
US8135595B2
(en)
|
2004-05-14 |
2012-03-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Computer systems and methods for providing health care
|
|
US7323347B2
(en)
*
|
2004-05-27 |
2008-01-29 |
Sensata Technologies, Inc. |
Biosensor surface structures and methods
|
|
JP4651663B2
(ja)
|
2004-05-28 |
2011-03-16 |
アジェンシス，インコーポレイテッド |
Ｐｓｃａタンパク質に結合する抗体および関連分子
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
EP1766077B1
(de)
|
2004-06-21 |
2012-03-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
|
|
CA2575557A1
(en)
*
|
2004-07-30 |
2006-02-09 |
Rosetta Inpharmatics Llc |
Prognosis of breast cancer patients
|
|
WO2006020768A2
(en)
|
2004-08-10 |
2006-02-23 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides
|
|
ES2406605T3
(es)
|
2004-08-20 |
2013-06-07 |
Buck Institute For Age Research |
Moléculas pequeñas que sustituyen o agonizan la función p53
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
US7850960B2
(en)
|
2004-12-30 |
2010-12-14 |
University Of Washington |
Methods for regulation of stem cells
|
|
WO2006094014A2
(en)
|
2005-02-28 |
2006-09-08 |
The Regents Of The University Of California |
Methods for diagnosis and treatment of endometrial cancer
|
|
EP2444099A1
(de)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
|
|
CN101500481B
(zh)
|
2005-04-05 |
2014-07-02 |
康宁股份有限公司 |
一种测定刺激事件对细胞产生的影响的方法
|
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
|
US20070099830A1
(en)
|
2005-04-21 |
2007-05-03 |
Massachusetts Institute Of Technology |
Sirt4 activities
|
|
ES2431315T3
(es)
|
2005-05-19 |
2013-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
|
|
AU2005332686B2
(en)
*
|
2005-06-03 |
2012-09-27 |
Ohr Pharmaceutical, Inc. |
Methods for providing palliative care with AVR118
|
|
HUE042197T2
(hu)
|
2005-07-19 |
2019-06-28 |
Stemgen S P A |
Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével
|
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
|
TWI333959B
(en)
*
|
2005-08-31 |
2010-12-01 |
Academia Sinica |
Methods and reagents for the analysis and purification of polysaccharides
|
|
US7943134B2
(en)
|
2005-08-31 |
2011-05-17 |
Academia Sinica |
Compositions and methods for identifying response targets and treating flavivirus infection responses
|
|
US7700565B2
(en)
*
|
2005-09-23 |
2010-04-20 |
Nitto Denko Corporation |
Peptide nucleic acid based guanidinium compounds
|
|
WO2007038172A2
(en)
*
|
2005-09-23 |
2007-04-05 |
Nitto Denko Corporation |
Guanidinium carriers
|
|
US7781209B2
(en)
*
|
2005-09-25 |
2010-08-24 |
Multispan, Inc. |
GPCR-expressing cell lines
|
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
|
EP2392647A1
(de)
|
2005-10-14 |
2011-12-07 |
MUSC Foundation For Research Development |
Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
|
|
EP1937718B1
(de)
|
2005-10-20 |
2017-12-06 |
Senomyx, Inc. |
Chimärische menschliche rezeptoren für süss-umami- und umami-süss-geschmack
|
|
CA2626852A1
(en)
*
|
2005-11-03 |
2007-05-18 |
Redpoint Bio Corporation |
High throughput screening assay for the trpm5 ion channel
|
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
|
DK2564864T3
(en)
|
2005-11-12 |
2015-04-07 |
Trustees Of The Leland Board Of |
FGF-2 related methods for the diagnosis and treatment of depression
|
|
US8014957B2
(en)
*
|
2005-12-15 |
2011-09-06 |
Fred Hutchinson Cancer Research Center |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof
|
|
CN101437933B
(zh)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
作为药物靶标的天然反义和非编码的rna转录物
|
|
US20090143238A1
(en)
*
|
2006-01-23 |
2009-06-04 |
Junghuei Chen |
Oligonucleotide matrix and methods of use
|
|
US7820883B2
(en)
*
|
2006-03-15 |
2010-10-26 |
Dow Agrosciences Llc |
Resistance to auxinic herbicides
|
|
US20090130108A1
(en)
|
2006-03-21 |
2009-05-21 |
The Regents Of The University Of California |
N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
|
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
|
US20080009552A1
(en)
*
|
2006-03-23 |
2008-01-10 |
Craig Pennell |
Markers of pre-term labor
|
|
US20070232556A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Montine Thomas J |
Methods and compositions for the treatment of neurological diseases and disorders
|
|
EP3398452B1
(de)
|
2006-04-21 |
2024-10-02 |
Firmenich Incorporated |
Essbare zusammensetzungen mit hochpotenten schmackhaften geschmackstoffen
|
|
WO2007129598A1
(ja)
|
2006-05-02 |
2007-11-15 |
Teikyo University |
グルタチオン増加物質のスクリーニング方法
|
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
|
CA2654701A1
(en)
*
|
2006-06-06 |
2007-12-21 |
Massachusetts Institute Of Technology |
Cholesterol-regulating complex of sirt1 and lxr and methods of use
|
|
ES2339960T3
(es)
|
2006-06-07 |
2010-05-27 |
NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH |
Metodos de cribado para compuestos que modulan la actividad de receptores acoplados a proteina g.
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
WO2008013861A2
(en)
*
|
2006-07-27 |
2008-01-31 |
Redpoint Bio Corporation |
Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
|
|
AU2007281082A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
|
WO2008022035A2
(en)
*
|
2006-08-10 |
2008-02-21 |
The Scripps Research Institute |
Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
|
|
WO2008019394A2
(en)
*
|
2006-08-11 |
2008-02-14 |
The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services |
Methods for treatment and diagnosis of psychiatric disorders
|
|
EP2423332A1
(de)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognosemarker und therapeutische Targets für Lungenkrebs
|
|
NZ575090A
(en)
|
2006-09-06 |
2012-02-24 |
Univ California |
Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers
|
|
US20100190689A1
(en)
|
2006-09-21 |
2010-07-29 |
University Of Rochester |
Compositions and methods related to protein displacement therapy for myotonic distrophy
|
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
|
US20100062000A1
(en)
*
|
2006-11-21 |
2010-03-11 |
The Regents Of The University Of California |
Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
|
|
US8133985B2
(en)
|
2006-12-15 |
2012-03-13 |
Panagene Inc. |
Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same
|
|
JP2010514804A
(ja)
*
|
2006-12-29 |
2010-05-06 |
ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ |
運動能力を高めるための方法
|
|
CA2674378A1
(en)
|
2007-01-03 |
2008-07-17 |
Burnham Institute For Medical Research |
Methods and compositions related to clot binding compounds
|
|
WO2008098182A1
(en)
|
2007-02-08 |
2008-08-14 |
University Of Utah Research Foundation |
Methods and compositions related to inhibition of viral entry
|
|
US20080229436A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Board Of Trustees Of The University Of Arkansas |
Methods for identifying modulators of lifespan and resistance to oxidative stress
|
|
AU2008287542C1
(en)
|
2007-06-01 |
2015-01-22 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
|
WO2009009662A1
(en)
*
|
2007-07-10 |
2009-01-15 |
University Of South Florida |
Method of predicting non-response to first line chemotherapy
|
|
WO2009021708A2
(en)
|
2007-08-13 |
2009-02-19 |
Baxter International Inc. |
Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
|
|
CN101828111B
(zh)
|
2007-08-21 |
2014-07-23 |
塞诺米克斯公司 |
人t2r苦味受体及其用途
|
|
US7875452B2
(en)
*
|
2007-10-01 |
2011-01-25 |
Redpoint Bio Corporation |
Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel
|
|
ES2908934T3
(es)
|
2007-10-04 |
2022-05-04 |
Zymogenetics Inc |
ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
|
WO2009050446A1
(en)
*
|
2007-10-15 |
2009-04-23 |
King's College London |
Viral therapeutic
|
|
EP2212693B1
(de)
|
2007-10-22 |
2015-04-22 |
The Regents of The University of California |
Biomarker für die pränatale diagnose
|
|
EP2219671A4
(de)
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
Verwendung von tam-rezeptorinhibitoren als immu-enhancer und tam-aktivatoren als immunsuppressoren
|
|
WO2009067243A2
(en)
|
2007-11-20 |
2009-05-28 |
Isis Pharmaceuticals Inc. |
Modulation of cd40 expression
|
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
|
KR101072899B1
(ko)
*
|
2008-01-21 |
2011-10-17 |
주식회사 파나진 |
아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용
|
|
AU2009332930A1
(en)
*
|
2008-02-01 |
2009-08-13 |
The Scripps Research Institute |
Methods for treating a condition characterized by dysfunction in protein homeostasis
|
|
CA2618163A1
(en)
|
2008-02-07 |
2009-08-07 |
K. W. Michael Siu |
Head and neck cancer biomarkers
|
|
US8105777B1
(en)
|
2008-02-13 |
2012-01-31 |
Nederlands Kanker Instituut |
Methods for diagnosis and/or prognosis of colon cancer
|
|
EP2257810B1
(de)
|
2008-03-05 |
2013-06-05 |
The Regents of the University of California |
Molekulare diagnose und klassifikation bösartiger melanome
|
|
EP2955222B1
(de)
|
2008-03-17 |
2018-09-12 |
The Scripps Research Institute |
Kombinierte chemische und genetische ansätze zur erzeugung von induzierten pluripotenten stammzellen
|
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
|
AU2009239491B2
(en)
|
2008-04-21 |
2014-07-17 |
Lawrence Livermore National Security, Llc |
Selective high-affinity polydentate ligands and methods of making such
|
|
EP2297347B1
(de)
|
2008-05-14 |
2017-03-08 |
Millennium Pharmaceuticals, Inc. |
Verfahren und kits zur überwachung der wirkung von immunmodulatoren auf die adaptive immunität
|
|
JP2011529708A
(ja)
|
2008-08-04 |
2011-12-15 |
ユニバーシティ オブ マイアミ |
自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
|
|
WO2010027641A2
(en)
*
|
2008-08-15 |
2010-03-11 |
Georgetown University |
Na channels, disease, and related assays and compositions
|
|
EP3216874A1
(de)
|
2008-09-05 |
2017-09-13 |
TOMA Biosciences, Inc. |
Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
|
|
WO2010033248A2
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
|
EP3587434A1
(de)
|
2008-09-23 |
2020-01-01 |
Alnylam Pharmaceuticals Inc. |
Chemische modifikationen von monomeren und oligonukleotiden mit click komponenten um liganden zu konjugieren
|
|
EP2568044B1
(de)
|
2008-09-29 |
2015-04-08 |
The Trustees of The University of Pennsylvania |
Auf Tumorgefässmarker gerichtete Impfstoffe
|
|
US8153606B2
(en)
|
2008-10-03 |
2012-04-10 |
Opko Curna, Llc |
Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
|
|
EP3260123A1
(de)
|
2008-11-06 |
2017-12-27 |
University of Miami |
Rolle von löslichem upar in der pathogenese von proteinurischer nierenerkrankung
|
|
US8735082B2
(en)
|
2008-11-10 |
2014-05-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene signature for predicting prognosis of patients with solid tumors
|
|
CA3029724A1
(en)
|
2008-11-10 |
2010-05-14 |
Muthiah Manoharan |
Lipids and compositions for the delivery of therapeutics
|
|
EP2370080A1
(de)
|
2008-12-02 |
2011-10-05 |
University of Utah Research Foundation |
Pde1 als zieltherapeutikum bei herzkrankheiten
|
|
ES2712074T3
(es)
|
2008-12-03 |
2019-05-09 |
Scripps Research Inst |
Cultivos de células madre
|
|
US8927511B2
(en)
|
2008-12-04 |
2015-01-06 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
|
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
JP6091752B2
(ja)
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
|
|
EP2370175A2
(de)
*
|
2008-12-16 |
2011-10-05 |
Bristol-Myers Squibb Company |
Verfahren zur unterdrückung von stiller tumorproliferation
|
|
ES2645869T3
(es)
|
2008-12-17 |
2017-12-11 |
The Scripps Research Institute |
Generación y mantenimiento de células madre
|
|
ES2560107T3
(es)
|
2009-02-12 |
2016-02-17 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
|
CA2753975C
(en)
|
2009-03-02 |
2017-09-26 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
EP2408919B1
(de)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
|
|
MX2011009752A
(es)
|
2009-03-17 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
|
|
US20100240065A1
(en)
*
|
2009-03-18 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Prolyl Hydroxylase Compositions and Methods of Use Thereof
|
|
US20100240069A1
(en)
*
|
2009-03-18 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity
|
|
KR20110140128A
(ko)
|
2009-03-27 |
2011-12-30 |
고조 인더스트리즈, 인크 |
포자-표면 상호작용을 길항하는 화합물을 스크리닝 및 사용하기 위한 조성물 및 방법
|
|
WO2010129799A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
|
|
JP5931720B2
(ja)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
|
|
US8957037B2
(en)
|
2009-05-18 |
2015-02-17 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
|
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
|
NZ712719A
(en)
|
2009-06-10 |
2017-03-31 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
JP5907866B2
(ja)
|
2009-06-26 |
2016-04-26 |
クルナ・インコーポレーテッド |
ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
|
|
WO2011011366A2
(en)
*
|
2009-07-20 |
2011-01-27 |
Constellation Pharmaceuticals |
Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
|
|
JP5755647B2
(ja)
|
2009-07-24 |
2015-07-29 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
|
|
CN102712925B
(zh)
|
2009-07-24 |
2017-10-27 |
库尔纳公司 |
通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
|
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
|
CN104313027B
(zh)
|
2009-08-11 |
2018-11-20 |
库尔纳公司 |
通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
|
|
DK3444613T3
(da)
|
2009-08-14 |
2021-06-21 |
Univ California |
Fremgangsmåder til diagnosticering og behandling af autisme
|
|
US20120149663A1
(en)
|
2009-08-18 |
2012-06-14 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
|
EP2467398B1
(de)
|
2009-08-20 |
2019-10-09 |
Poseida Therapeutics, Inc. |
Trpc4-hemmer und ihre verwendung
|
|
EP2467482A4
(de)
|
2009-08-21 |
2013-12-11 |
Curna Inc |
Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
|
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー，インコーポレイテッド |
‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
|
|
ES2664591T3
(es)
|
2009-09-25 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
|
|
EP2485768A1
(de)
|
2009-10-07 |
2012-08-15 |
Sanford-Burnham Medical Research Institute |
Verfahren und zusammensetzungen im zusammenhang mit an gerinnseln bindenden lipidzusammensetzungen
|
|
ES2365343B1
(es)
|
2009-11-19 |
2012-07-10 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
Uso de cd98 como marcador de receptividad endometrial.
|
|
JP5911805B2
(ja)
|
2009-11-20 |
2016-04-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
|
|
AU2010328336B2
(en)
|
2009-12-07 |
2017-03-02 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
DK2513310T3
(en)
|
2009-12-16 |
2018-02-05 |
Curna Inc |
TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
|
|
WO2011075725A1
(en)
|
2009-12-18 |
2011-06-23 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
|
EP2512449B1
(de)
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
|
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
ES2661387T3
(es)
|
2009-12-23 |
2018-03-28 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
|
|
EP2519634B1
(de)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
|
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー，インコーポレイテッド |
核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
|
|
DK2519632T3
(en)
|
2009-12-31 |
2018-07-23 |
Curna Inc |
TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
|
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
|
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
|
US9216189B2
(en)
|
2010-01-25 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
|
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
|
US20130137584A1
(en)
|
2010-02-01 |
2013-05-30 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
|
ES2600356T3
(es)
|
2010-02-22 |
2017-02-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
|
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
|
US8980856B2
(en)
|
2010-04-02 |
2015-03-17 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
|
|
US20140187430A1
(en)
|
2010-04-06 |
2014-07-03 |
George Washington University |
Compositions and Methods for Identifying Autism Spectrum Disorders
|
|
JP5978203B2
(ja)
|
2010-04-09 |
2016-08-24 |
カッパーアールエヌエー，インコーポレイテッド |
Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
|
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
EP2957636B1
(de)
|
2010-05-03 |
2020-04-01 |
CuRNA, Inc. |
Behandlung von sirtuin 3 (sirt3)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt3
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
DK2576784T3
(en)
|
2010-05-26 |
2018-02-26 |
Curna Inc |
TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
|
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
|
US9228240B2
(en)
|
2010-06-03 |
2016-01-05 |
California Institute Of Technology |
Methods for detecting and quantifying viable bacterial endo-spores
|
|
EP2400304A1
(de)
|
2010-06-22 |
2011-12-28 |
Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) |
Verfahren zur Charakterisierung intermolekularer Interaktionen
|
|
DK2585596T3
(da)
|
2010-06-23 |
2021-04-06 |
Curna Inc |
Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー，インコーポレイテッド |
Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
|
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
EP2606165B1
(de)
|
2010-08-16 |
2016-10-12 |
Sinai Health System |
Marker für den männlichen urogenitaltrakt
|
|
AU2011293635B2
(en)
|
2010-08-24 |
2015-11-26 |
Children's Medical Center Corporation |
Methods for predicting anti-cancer response
|
|
EP3572528A1
(de)
|
2010-09-24 |
2019-11-27 |
The Board of Trustees of the Leland Stanford Junior University |
Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
|
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
|
EP2643484A4
(de)
|
2010-11-22 |
2014-04-16 |
Univ California |
Verfahren zur identifizierung eines rna-transkripts zellulären ursprungs
|
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー，インコーポレイテッド |
Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
|
|
CN103380212B
(zh)
|
2010-12-22 |
2017-04-05 |
菲特治疗公司 |
用于单细胞分选与增强ipsc重新编程的细胞培养平台
|
|
JP5902197B2
(ja)
|
2011-01-11 |
2016-04-13 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
|
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
|
DK2675893T3
(en)
|
2011-02-18 |
2019-04-15 |
Scripps Research Inst |
Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
|
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
|
JP6205345B2
(ja)
|
2011-03-28 |
2017-09-27 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
ウイルス侵入の阻害に関する方法および組成物
|
|
US20120301904A1
(en)
|
2011-04-26 |
2012-11-29 |
Prosetta Antiviral, Inc |
Multiprotein assemblies
|
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
|
ES2653247T3
(es)
|
2011-06-09 |
2018-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
|
|
JP6117194B2
(ja)
|
2011-06-17 |
2017-04-19 |
ミリアド・ジェネティックス・インコーポレイテッド |
アレル不均衡を評価するための方法および材料
|
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
WO2013018690A1
(ja)
|
2011-07-29 |
2013-02-07 |
国立大学法人徳島大学 |
Erap1由来ペプチド及びその使用
|
|
JP6342805B2
(ja)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
|
|
MX365525B
(es)
|
2011-09-06 |
2019-06-06 |
Curna Inc |
Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
|
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換ｐｅｇ化脂質
|
|
EP2764122B1
(de)
|
2011-10-03 |
2017-12-06 |
Celmatix, Inc. |
Verfahren und vorrichtungen zur bewertung des risikos einer angenommenen auswirkung der entwicklung eines zustands
|
|
CN106978487A
(zh)
|
2011-10-28 |
2017-07-25 |
米伦纽姆医药公司 |
对nedd8活化酶(nae)抑制剂的反应的生物标记
|
|
TR201815535T4
(tr)
|
2011-12-16 |
2018-11-21 |
Poseida Therapeutics Inc |
Ağrının tedavisinde veya bunun önlenmesinde kullanıma yönelik TRPC4 modülatörleri.
|
|
EP3660161B1
(de)
|
2011-12-21 |
2024-07-31 |
Myriad Genetics, Inc. |
Methoden und materialien zur bewertung des heterozygositätsverlustes
|
|
HK1205952A1
(en)
|
2012-02-16 |
2015-12-31 |
The Penn State Research Foundation |
Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
|
|
CA3080441C
(en)
|
2012-02-23 |
2026-01-06 |
The Technical University Of Denmark |
Methods for predicting anti-cancer response
|
|
US9408832B2
(en)
|
2012-03-14 |
2016-08-09 |
University Of Central Florida Research Foundation, Inc. |
LIM kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
|
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
EP2841450A2
(de)
|
2012-04-24 |
2015-03-04 |
University of Miami |
Perforin-2-abwehr gegen invasive und multiwirkstoffresistente pathogene
|
|
US9347948B2
(en)
|
2012-06-04 |
2016-05-24 |
The Scripps Research Institute |
Phenyl glyoxal probes
|
|
AU2013273466B2
(en)
|
2012-06-07 |
2018-11-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
|
|
WO2014018535A1
(en)
|
2012-07-25 |
2014-01-30 |
Salk Institute For Biological Studies |
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
|
|
US9750705B2
(en)
|
2012-08-31 |
2017-09-05 |
The Regents Of The University Of California |
Agents useful for treating obesity, diabetes and related disorders
|
|
SG11201502331RA
(en)
|
2012-09-26 |
2015-04-29 |
Univ California |
Modulation of ire1
|
|
US10662477B2
(en)
|
2012-10-01 |
2020-05-26 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
US9177098B2
(en)
|
2012-10-17 |
2015-11-03 |
Celmatix Inc. |
Systems and methods for determining the probability of a pregnancy at a selected point in time
|
|
US10162800B2
(en)
|
2012-10-17 |
2018-12-25 |
Celmatix Inc. |
Systems and methods for determining the probability of a pregnancy at a selected point in time
|
|
US20140120116A1
(en)
|
2012-10-26 |
2014-05-01 |
The Chinese University Of Hong Kong |
Treatment of cancer using smad3 inhibitor
|
|
US10206911B2
(en)
|
2012-10-26 |
2019-02-19 |
Memorial Sloan-Kettering Cancer Center |
Androgen receptor variants and methods for making and using
|
|
US9836577B2
(en)
|
2012-12-14 |
2017-12-05 |
Celmatix, Inc. |
Methods and devices for assessing risk of female infertility
|
|
DK2954323T3
(da)
|
2013-02-07 |
2020-07-20 |
Univ California |
Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling
|
|
WO2014160080A1
(en)
|
2013-03-14 |
2014-10-02 |
Children's Medical Center Corporation |
Cancer diagnosis, treatment selection and treatment
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
|
EP2986717A1
(de)
|
2013-04-19 |
2016-02-24 |
The Regents of The University of California |
Lone-star-virus
|
|
WO2015025323A1
(en)
|
2013-08-21 |
2015-02-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Treatment of mood and stress related disorders
|
|
US10626178B2
(en)
|
2013-08-21 |
2020-04-21 |
Raz Yirmiya |
Treatment of mood and stress related disorders
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
WO2015057461A2
(en)
|
2013-10-18 |
2015-04-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
|
|
ES2909899T3
(es)
|
2013-12-09 |
2022-05-10 |
Inst Curie |
Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
|
|
WO2015089338A2
(en)
|
2013-12-11 |
2015-06-18 |
Sloan-Kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
|
US10280169B2
(en)
|
2013-12-11 |
2019-05-07 |
Biogen Ma Inc. |
Biaryl bruton's tyrosine kinase inhibitors
|
|
ES2837437T3
(es)
|
2013-12-20 |
2021-06-30 |
Univ Lausanne |
Usos diagnósticos, pronósticos y terapéuticos de ARN largos no codificantes para cardiopatías y medicina regenerativa
|
|
WO2015118407A2
(en)
|
2014-01-29 |
2015-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
|
KR102340553B1
(ko)
|
2014-03-04 |
2021-12-21 |
페이트 세러퓨틱스, 인코포레이티드 |
개선된 재프로그래밍 방법 및 세포 배양 플랫폼
|
|
WO2015136509A2
(en)
|
2014-03-14 |
2015-09-17 |
Genesis Theranostix Korlatolt Felelossegu Tarsasag |
Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
|
|
WO2016011377A1
(en)
|
2014-07-17 |
2016-01-21 |
Celmatix Inc. |
Methods and systems for assessing infertility and related pathologies
|
|
JP6877334B2
(ja)
|
2014-08-15 |
2021-05-26 |
ミリアド・ジェネティックス・インコーポレイテッド |
相同組換え欠損を評価するための方法および材料
|
|
KR102617137B1
(ko)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
AU2016225000B2
(en)
|
2015-02-27 |
2021-04-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
|
US10246424B2
(en)
|
2015-04-10 |
2019-04-02 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
US10196701B2
(en)
|
2015-06-01 |
2019-02-05 |
The Penn State Research Foundation |
Hepatitis B virus capsid assembly
|
|
WO2016207313A1
(en)
|
2015-06-24 |
2016-12-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for detecting protein-protein interactions
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
EP3356339A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
EP3356349A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
AU2016338680B2
(en)
|
2015-10-16 |
2022-11-17 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
|
EP3364977A4
(de)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
Verfahren zum screening von inhibitoren von ras
|
|
WO2017079572A1
(en)
|
2015-11-04 |
2017-05-11 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, evaluation and treatment of patients having multiple myeloma
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018036503A1
(en)
|
2016-08-25 |
2018-03-01 |
The Chinese University Of Hong Kong |
Fecal bacterial markers for colorectal cancer
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
AU2017378487B2
(en)
|
2016-12-15 |
2022-03-31 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
EP3573964A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573970A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
|
|
EP3596117A4
(de)
|
2017-03-17 |
2021-01-13 |
The Johns Hopkins University |
Gezielte epigenetische therapie gegen das distale regulatorische element der tgfb2-expression
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
AU2018248423A1
(en)
|
2017-04-04 |
2019-10-17 |
Loma Linda University |
Biologic for the treatment of cancer
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
MX2019013954A
(es)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras.
|
|
ES2947336T3
(es)
|
2017-09-01 |
2023-08-07 |
Univ Johns Hopkins |
Terapia epigenética dirigida para el aneurisma aórtico hereditario
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
EP3692073A4
(de)
|
2017-10-03 |
2021-05-26 |
Cedars-Sinai Medical Center |
Verfahren zum targeting des immuncheckpunkt-pd1-signalwegs zur behandlung von lungenfibrose
|
|
US11419947B2
(en)
|
2017-10-30 |
2022-08-23 |
Massachusetts Institute Of Technology |
Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
|
|
WO2019109016A1
(en)
|
2017-12-01 |
2019-06-06 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods for treatment with nae inhibitors
|
|
EP3553182A1
(de)
|
2018-04-11 |
2019-10-16 |
Université de Bourgogne |
Verfahren zum nachweis von somatischen genetischen anomalien, kombination von fangsonden und nachweiskit
|
|
US20210247386A1
(en)
|
2018-04-26 |
2021-08-12 |
Technion Research & Development Foundation Limited |
A device and method for determining cell indentation activity
|
|
EP3829580A1
(de)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclische spiroverbindungen und ihre verwendung zur behandlung von krebs
|
|
ES3023937T3
(en)
|
2018-10-31 |
2025-06-03 |
The Westmead Institute For Medical Res |
Pharmaceutical compositions for use in treating an hbv or hdv infection
|
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
|
EP3677693A1
(de)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimäre gentranskripte (tcgts) als krebsbiomarker
|
|
WO2021002984A1
(en)
|
2019-05-30 |
2021-01-07 |
Massachusetts Institute Of Technology |
Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
|
|
EP3997225A1
(de)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von epilepsie
|
|
EP4038222A4
(de)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
|
|
EP4061943A1
(de)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense-oligonukleotide und deren verwendung zur behandlung von krebs
|
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
|
CA3192695A1
(en)
|
2020-09-16 |
2022-03-24 |
Novigenix Sa |
Biomarkers for immune checkpoint inhibitors treatment
|
|
EP4247427A4
(de)
|
2020-11-19 |
2025-04-09 |
The Chinese University of Hong Kong |
Risikobeurteilung für kolorektale adenomrezidiven durch nichtinvasive mittel
|
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
|
US20240247264A1
(en)
|
2021-05-28 |
2024-07-25 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
|
|
WO2023081167A2
(en)
|
2021-11-02 |
2023-05-11 |
The Regents Of The University Of California |
P-selectin mutants and modulation of integrin-mediated signaling
|
|
US20250092106A1
(en)
|
2022-01-25 |
2025-03-20 |
The Regents Of The University Of California |
Vegf mutants and modulation of integrin-mediated signaling
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
CN120752339A
(zh)
|
2023-01-06 |
2025-10-03 |
国家医疗保健研究所 |
静脉内施用用于治疗疼痛的反义寡核苷酸
|
|
WO2024160683A1
(en)
|
2023-01-30 |
2024-08-08 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Pou5f1b inhibitors
|
|
GB2626789A
(en)
*
|
2023-02-03 |
2024-08-07 |
Exactmer Ltd |
Deprotection processes and cation scavengers for use in the same
|
|
WO2024197185A1
(en)
|
2023-03-21 |
2024-09-26 |
The Broad Institute, Inc. |
Methods and compositions for dissecting organelle physiology
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
EP4632079A1
(de)
|
2024-04-09 |
2025-10-15 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Verfahren zur bestimmung des risikos, komplikationen im zusammenhang mit allo-hsct zu entwickeln
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|